Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

Exclusion Criteria

• •Treatment within specific time windows before the baseline visit for the management of atopic dermatitis such as topical or systemic corticosteroids, biologic or investigational therapies and/or phototherapy.
• •Known history of, or suspected, significant current immunosuppression, including history of invasive opportunistic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration.
• •Weight \<40 kg or \>150 kg at Baseline.
• •Treatment with a live (attenuated) immunization within 12 weeks prior to Baseline.
• •Men and women (of reproductive potential) unwilling to use birth control and women who are pregnant or breastfeeding.
• •Any malignancies or history of malignancies prior to Baseline (except for non-melanoma skin cancer that has been excised and cured for more than 3 years prior to Baseline; in situ cervical carcinoma that has been excised and cured).
• •Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C at the screening visit.
• •Severe concomitant illness that would in the Investigator's opinion inhibit the patient's participation in the study, including for example, but not limited to, hypertension, renal disease, neurological conditions, heart failure and pulmonary disease.
• •In the Investigator's opinion, any clinically significant laboratory results from the clinical chemistry, hematology or urinalysis tests at the Screening Visit.
• •Concurrent participation in any other clinical study, including non-interventional studies.
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.